Betashares Global Healthcare ETF







29 February 2024

Objective

DRUG aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

Benefits



Healthcare

A global growth opportunity - ageing populations, rising living standards and ongoing medical advancements are expected to support increasing demand for healthcare products and services.



Simple access to global healthcare giants

Invest in a diversified portfolio of the world's leading healthcare companies, such as Johnson & Johnson, Pfizer and Roche, in one trade.



Cost-effective

Passive, index-tracking approach means no 'active manager' fees.



Reduced currency risk

Foreign currency exposure hedged back to the Australian dollar.


Performance

PERIOD	1 mth	3 mth	6 mth	1 yr	3 yr (p.a.)	5 yr (p.a.)	10 yr (p.a.)	Inception (p.a.)
FUND	2.95%	9.98%	7.22%	14.36%	9.32%	9.08%	-	8.68%
INDEX	2.99%	10.10%	7.50%	14.82%	9.72%	9.37%	9.65%	9.04%

Calendar year performance

PERIOD	YTD	2023	2022	2021	2020	2019	2018	2017
FUND	6.78%	1.40%	-2.93%	22.34%	5.87%	20.55%	3.95%	17.56%
INDEX	6.84%	1.82%	-2.56%	22.78%	6.40%	20.24%	4.32%	18.16%

Value of \$100 invested since inception



Source: Betashares, Bloombera, Past performance is not indicative of future performance. Fund returns are calculated in A\$ using net asset value per unit at the start and end of the specified period and do not reflect the brokerage or bid-ask spread that investors may incur when buying and selling units on the ASX. Returns are after fund management costs, assume reinvestment of any

Fund information

Betashares Funds can be bought or sold during the trading day on the ASX, and trade like shares.

ASX CODE DRUG **BLOOMBERG CODE** DRUG AU **IRESS CODE DRUG.AXW** DISTRIBUTIONS SEMI-ANNUAL MGT FEE 0.47% P.A. **EXPENSES** ESTIMATED AT 0.10% P.A. **FUND INCEPTION 4 AUG 16**

About the index

INDEX

NASDAQ GLOBAL EX-AUSTRALIA **HEALTHCARE HEDGED AUD**

BLOOMBERG CODE NOXAUHHN

FORWARD P/E RATIO 19.24X

P/B RATIO 5.00X WEIGHTED AVG MARKET CAP A\$385.3B **NO OF COMPONENTS** 62

Categorisation

GLOBAL HEALTHCARE

SECTOR EXPOSURE

CAPITAL APPRECIATION

Betashares Global Healthcare ETF – Currency Hedged





29 February 2024

Sector allocation



Country allocation



Top 10 exposures

Company	Weighting			
Eli Lilly & Co	9.3%			
UnitedHealth Group	6.5%			
Novo Nordisk	6.1%			
Johnson & Johnson	5.9%			
Merck & Co Inc	4.9%			
AbbVie Inc	4.5%			
Thermo Fisher Scientific Inc	3.5%			
Novartis AG	3.5%			
Abbott Laboratories	3.1%			
Roche Holding AG	2.9%			

Distributions

12 mth distribution yield (%)

0.3%

Yield is calculated by summing the prior 12-month per unit distributions divided by the closing NAV per unit at the end of the relevant period. Yield will vary and may be lower at time of investment. Past performance is not indicative of future performance.

This information has been prepared by Betashares Capital Ltd (ABN 78 139 566 868 AFSL 341181) (Betashares), the issuer of the Fund. It does not take into account any person's objectives, financial situation or needs. Investors should consider the appropriateness of the information taking into account such factors and seek financial advice. Before making an investment decision, investors should read the Product Disclosure Statement (PDS), available at www.betashares.com.au, and consider whether the Fund is appropriate for their circumstances. A Target Market Determination (TMD), which sets out the class of consumers in the target market for the Fund, is also available at www.betashares.com.au/atraget-market-determinations. An investment in the Fund is subject to investment risk and the value of units may go down as well as up. Betashares does not guarantee the performance of the Fund, the repayment of capital or any rate of return.